Immunization of guinea pigs with Salmonella delivered anti-Brucella formulation reduces organs bacterial load and mitigates histopathological consequences of Brucella abortus 544 challenge

•Assessment of Salmonella vectored anti-Brucella vaccine formulated with lipopolysaccharide in guinea pigs.•The formulation exhibited safety on general health, postmortem, and histological standpoints.•The formulation reduces organ challenge bacterial loads and mitigations of histopathological consequences. With an objective to generate safe and effective anti-Brucella vaccine, an attenuated live Salmonella Typhimurium vector delivering heterologous Brucella immunogenic proteins SOD, Omp19, BLS, and PrpA formulated with purified Brucella abortus lipopolysaccharide was evaluated on a guinea pig model. This model represents high susceptibility to Brucella infections and showed similarities in reproducing human pathologies. On safety perspectives, the vaccine formulation induced no observable alterations on general health and histology of the vaccinated guinea pigs. Upon virulent strain 544 challenge, a protective index of 1.52 was observed based on differential splenic counts. Post-challenge histopathology revealed that Brucella induced microgranulomas and fatty degenerations were prominent in the organs of non-immunized animals as compared to immunized animals. With these findings, it is suggestive that this live Brucella-free vaccine formulation is safe and protective on a sensitive guinea pig model and may be suitable for further human-related vaccine trials.